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S U M M A R Y
Objectives: Burkholderia cepacia has been linked to healthcare-associated infections and colonization
caused by contamination of alcohol-free mouthwash used in patients undergoing mechanical
ventilation. The purpose of our study was to establish the source of a clustering of healthcare-
associated B. cepacia isolates in patients on mechanical ventilation in the intensive care unit (ICU).
Methods: During April 2012 the Infection Control Committee became concerned when B. cepacia was
isolated from tracheal aspirate cultures of three ICU patients. The medical records for the years 2011 and
2012 were reviewed to identify further cases. Cultures of potential reservoirs were done. Isolates from
patients and an alcohol-free mouthwash were submitted to multilocus sequence typing (MLST) analysis
and antimicrobial resistance testing.
Results: Four patients with positive cultures for B. cepacia were identiﬁed before the review of the
medical records for the years 2011 and 2012. Nine further cases were identiﬁed in the review, deﬁned as
a patient with pneumonia who had a culture of respiratory secretions that was positive for B.
cepacia. Three were cases of infection and 10 were colonizations. All of the isolates from patients (J, K, L,
and M) and mouthwash samples (B19, B20, and B21) were genetically identical by MLST analysis.
Conclusions: Our ﬁndings strongly suggest that alcohol-free mouthwash solution intrinsically
contaminated with B. cepacia was the source of these colonizations and infections involving adults
in the ICU.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Burkholderia cepacia is a species of bacterium widely distributed
in natural environments such as water, soil, and agricultural
products. B. cepacia is not virulent in healthy people, but is a serious
opportunistic pathogen in immunocompromised and cystic ﬁbrosis
patients. B. cepacia has been linked to healthcare-associated
outbreaks caused by the contamination of medical devices,1,2
antiseptic solutions, parenteral and nebulized medications,3,4 and
other environmental sources.5 It has also been implicated in* Corresponding author. Tel.: +593 2242777; fax: +593 2253770.
E-mail address: jzurita@hcjb.org (J. Zurita).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).healthcare-associated outbreaks caused by the contamination of
alcohol-free mouthwash solutions.6,7Mouthwashes are used widely
in patients undergoing mechanical ventilation. Such patients are
highly vulnerable to pathogens that typically cause upper respira-
tory tract infections because of their inability to maintain the
mucociliary and cough mechanisms that normally protect the lower
respiratory tract.8These bacteria have also contaminated many drug
products, leading to public health concerns.
From March 2011 through May 2012 a cluster of healthcare-
associated B. cepacia isolates was identiﬁed among ventilated
patients in a general medical intensive care unit (ICU). This study
reports the results of an investigation to determine the source of
this B. cepacia and summarizes our experience with the manage-
ment of these colonizations and infections.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
J. Zurita et al. / International Journal of Infectious Diseases 29 (2014) 96–99 972. Methods
2.1. Hospital and patients
Vozandes Hospital is a 75-bed private, acute care teaching
hospital in Quito, Ecuador; eight of these beds are in the ICU. The
study was performed by the Infection Control Committee.
During the month of April 2012, B. cepacia was cultured from
the tracheal aspirates of three patients. All of them were
hospitalized in the ICU. The B. cepacia was isolated on April
16 in two cases, and on April 27 in another. A fourth case occurred
on May 2. As part of routine surveillance for ventilator-associated
pneumonia (VAP), this ﬁnding prompted an investigation of these
cases. The bacterial strains were saved for further analysis.
With the results of these cultures, we proceeded to review the
medical records of any patient who had been in the ICU and who
had had a respiratory specimen culture positive for B. cepacia. We
reviewed the medical records for the years 2011 and 2012. All
results of routine cultures from patients admitted to the ICU and all
medical records from patients whose respiratory sample was
positive for B. cepacia were reviewed. A case was deﬁned as a
patient with pneumonia who had a respiratory sample culture that
was positive for B. cepacia (sputum, or bronchial lavage, or tracheal
aspirate), elevated procalcitonin and C-reactive protein, and had a
pulmonary inﬁltration. All of the patients required mechanical
ventilation. In order to identify the reservoir of B. cepacia, we
cultured samples from solutions used commonly in patients
undergoing mechanical ventilation, i.e. hydrating cream, povi-
done–iodine solution, water supplies, distilled water, and alcohol-
free mouthwash.
2.2. Microbiological investigations
Samples from the patients and samples from opened (one per
patient) and unopened 15-ml bottles of the mouthwash were
cultured under laboratory standards. The samples were cultured in
blood, chocolate, and MacConkey agars. Strain identiﬁcation was
carried out using the API 20 NE strip system (bioMe´rieux, Marcy
l’Etoile, France) and Vitek 2 system (bioMe´rieux, Marcy l’Etoile,
France). The antimicrobial susceptibility of the four isolates from
the patients and three isolates from the mouthwash was
determined by Etest (M.I.C Evaluator Strip, Oxoid, UK) in
Mueller–Hinton agar and by Vitek 2 system, in accordance with
the guidelines of the Clinical and Laboratory Standards Institute
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Figure 1. Temporal distribution of patient cases by month. Burkholderia cepacia was is
ventilated.2.3. Multilocus sequence typing (MLST) analysis
Seven strains were sent to the Institute of Microbiology at San
Francisco University in Quito to investigate their clonal relation-
ship by MLST. Four of them were isolated from clinical samples
obtained from patients in April through May 2012 (J, K, L, and M).
Three strains were isolated from mouthwash samples used in the
same hospital. An isolate from the bacterial collection belonging to
another conﬁrmed outbreak was used in the MLST analysis as an
external strain. Genomic DNA was isolated with DNAzol Reagent
following the manufacturer’s instructions. Ampliﬁcation of the
seven most variable loci was performed as described previously.9
Sequences were determined by Functional Biosciences Inc. (South
Rosa, USA). The sequences of the seven loci were aligned using
ClustalW method, except for the trpB gene which was aligned
using the MUSCLE alignment method (MEGA version 5.05).
3. Results
From March 2011 to May 2012, a total of 13 patients had
cultures positive for B. cepacia. All of the positive cultures came
from tracheal aspirates. Four cases were identiﬁed over a short
period of time (April 16 through May 2), with two of them
occurring on the same day. There was concern about a possible
outbreak, and we subsequently identiﬁed nine patients retrospec-
tively (Figure 1). All 13 patients were in the ICU and were
ventilated. Three patients developed VAP. This was caused by B.
cepacia in two of them; the other patient developed VAP caused by
another pathogen (see Supplementary Material). Ten patients
were considered to be colonized. The dates of isolation coincided
with the start date of the use of the same batch of mouthwash.
Patients ranged in age from 47 to 92 years (mean 72.5 years);
four were female and nine were male. The patients had been
admitted to hospital with various diagnoses. All but two were
elderly. None had a medical condition associated with B. cepacia
infection (e.g., cystic ﬁbrosis or chronic granulomatous disease).
After B. cepacia was identiﬁed, ﬁve patients were treated with oral
trimethoprim–sulfamethoxazole alone and one patient was
treated with oral trimethoprim–sulfamethoxazole and merope-
nem; two of the ﬁve patients who were treated with oral
trimethoprim–sulfamethoxazole alone died and the one patient
who received trimethoprim–sulfamethoxazole and meropenem
died. These three patients apparently died of the disease process
for which they had been hospitalized. It is impossible to determine
whether the cause of death in these three patients was a B. cepacia    DEC    JAN    FEB    MAR    APR    MAY    JUN   JU L    AUG
2012
1 1 1
1
1
Beginning of  investigation
April 16
Use of  comercial 
mouthwash ended
May 3
B. cepacia was isolated from
respira tory samp les
Two isolat ions: April  16
One isolat ion : April  27
One isolat ion : May 2
1
olated from respiratory samples. All patients were admitted to the ICU and were
Table 1
Allelic proﬁles, corresponding sequence type (ST), and number of polymorphic sites
in the seven loci of the Bclin and hospital isolates.
Gene Allelic proﬁle
of hospital
isolates
Allelic proﬁle
of Bclin
straina
Number of
polymorphic
sites
Sequence
length
analyzed (bp)
atpD 64 16 8 443
gltB 80 108 7 400
gyrB 546 326 25 454
recA 217 49 29 393
lepA 122 68 11 397
phaC 288 185 12 385
trpB 214 226 18 301
ST 762 395 - -
a The strain Bclin was isolated from a urine sample obtained using a Foley
catheter from a 66-year-old patient in a local hospital, May 24, 2011. It was
identiﬁed by API 20 NE strip system (bioMe´rieux, Marcy l’Etoile, France). According
to the PubMLST database, ST395 was previously characterized in 2012 and
corresponds to a Burkholderia cenocepacia strain isolated from a urine sample in
2006 in the Institut Fe´de´ratif de Biologie, Hoˆpital Purpan, France.
J. Zurita et al. / International Journal of Infectious Diseases 29 (2014) 96–9998infection. Two of the ﬁve patients who were treated with oral
trimethoprim–sulfamethoxazole alone and the patient treated
with trimethoprim–sulfamethoxazole plus meropenem developed
VAP caused by another pathogen. One patient was treated with
meropenem only and developed VAP. Three additional patients
were treated with ceftazidime, and none of them died. Three
patients were not treated.
We looked for a potential reservoir of B. cepacia and cultured
samples from other solutions such as hydrating cream, povidone-
iodine solution, water supplies, and distilled water, the latter
because there had already been an outbreak caused by sterile
distilled water contaminated with B. cepacia.10 Eighteen samples
were cultured. All of them were culture-negative for B. cepacia. We
ﬁnally isolated B. cepacia from the alcohol-free mouthwash. A
quantitative culture of this commercial product revealed 105 CFU/
ml of B. cepacia. One batch of the mouthwash from the same
manufacturer was found in the hospital supply department.
Samples were cultured from unopened bottles of mouthwash
belonging to the same batch as had been distributed in the ICU.
Batches distributed in that period were highly contaminated.
Three samples of this product were studied in molecular assays.
Samples of the mouthwash were uniformly positive for the
same organism. The hospital supply department had been
purchasing this product from this source for 13 months before
the B. cepacia was identiﬁed. Four isolates recovered from patients
in this investigation and three isolates recovered from samples of
this commercial mouthwash were investigated using phylogenetic
analysis. MEGA 5.05 software was used to construct a gene tree of
the concatenated sequences (5018 bp) for each isolate by the
neighbour-joining method. The signiﬁcance of branching within
the tree was evaluated by bootstrap analysis of 500 computer-
generated trees. For MLST we used the same size in the seven genes
for the alignment and no gaps were found. All of the isolates from
patients (J, K, L, and M) and mouthwash samples (B19, B20, and
B21) were shown by MLST analysis to be genetically identical
(Figure 2). All of the isolates shared the same allelic proﬁle
(Table 1). Our study identiﬁed two new allele sequences (gyrB
546 and phaC 288) and a new sequence type (ST762) that
corresponded to the outbreak strain. The data were submitted to
the B. cepacia complex PubMLST database (http://pubmlst.org/bcc/
). In addition, all isolates (four from the patients and three from the
mouthwash) were susceptible to the antimicrobials tested:
trimethoprim–sulfamethoxazole (<20 mg/ml), ceftazidime
(4 mg/ml), and levoﬂoxacin (2 mg/ml) by Vitek 2 cards; merope-
nem (1 mg/ml) and minocycline (2 mg/ml) by Etest.
On May 3, the use of the mouthwash product in the hospital was
discontinued and the last isolate of B. cepacia was obtained on the
same date. B. cepacia was recovered during the period when the
implicated mouthwash was being used by the hospital. As soon as
the commercial mouthwash was conﬁrmed to be contaminatedFigure 2. Neighbour-joining tree of the concatenated sequences of the seven genes.
J, K, L, and M are patient isolates; B19, B20, and B21 are mouthwash isolates; Bclin is
the Burkholderia cepacia clinical isolate used as control.with B. cepacia, the product was removed from the hospital and a
formal report was submitted to the Ecuador Ministry of Health.
Intrinsic contamination of the mouthwash was conﬁrmed by the
Instituto Nacional de Investigacio´n en Salud Pu´blica (INSPI). The
methods used to aliquot and distribute the product and the extent
to which this mouthwash had been used in other hospitals were
investigated by the Ministry of Health. There are no ofﬁcial ﬁgures
yet, but another private hospital that used the same product has
also reported patients infected with B. cepacia.
4. Discussion
B. cepacia is a common organism that typically causes
respiratory tract infections in ICU patients. The severity of an
infection or colonization by B. cepacia may be different for
individual patients. However, overall, pulmonary colonization
reduces survival by 50%; about a third to a half of patients develop
B. cepacia syndrome, a rapidly fatal necrotizing pneumonia.11
Initially a few B. cepacia isolates were recovered and the
organism was not consistently isolated each month. A full
investigation was not initiated until after B. cepacia was
documented in a patient and after several patients had the same
organism recovered from tracheal aspirates in the same month
(two on the same day). A review of the medical records for
2011 and 2012 identiﬁed nine previous isolates that were
consistent with the timing of use of the mouthwash batch. These
infections and colonizations were caused by the alcohol-free
mouthwash contaminated by B. cepacia. Mouthwash has been
implicated in outbreaks of pneumonia due to B. cepacia in other
countries.12,13
All ICU patients in this study had undergone intubation and
mechanical ventilation during their ICU stay. As a part of routine
oral care for mechanically ventilated patients, they had had their
mouths swabbed with an alcohol-free mouthwash. The active
ingredient in this product is chlorhexidine 0.12%. B. cepacia is a
well-known healthcare-associated pathogen that is intrinsically
resistant to aminoglycosides and ﬁrst- and second-generation
cephalosporins. This multiple antibiotic resistance of B. cepacia has
been attributed to an impermeable selective outer membrane, an
efﬂux pump mechanism, bioﬁlms, and/or the production of an
inducible chromosomal beta-lactamase.14–16 However in this
study, all of the isolates were sensitive to the ﬁve antimicrobial
agents studied. All of the isolates showed the same antimicrobial
susceptibility pattern.
Although B. cepacia does not appear to survive on completely
dry surfaces for more than 1 week, it can survive for many months
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including contact with hard surfaces. Perhaps most important to
note is this organism’s ability to remain viable under harsh
conditions (e.g., organic solvents, antiseptics, low nutrients, etc.)
for many months. Given the nature of this microorganism, its
ability to grow in low-nutrient conditions, and resistance to
chemical preservatives, it is important to consider the relatively
high patient risk when this microorganism is present in
manufacturing equipment, components, raw materials, or the
potable water used in manufacturing pharmaceutical products.
It sounds paradoxical, but no antiseptic products are free from
the possibility of bacterial contamination. Sometimes manufactur-
ing practices are substandard. The literature talks about good
manufacturing practices, which have to be scrupulously respected.
Another possibility is that B. cepacia is becoming increasingly
resistant to commonly used antiseptics, resulting in its multiplying
to unacceptable levels. However, this last remark brings us back to
the issue of good manufacturing practices, which should be
supervised by competent authorities. In some quality control
situations, the review is limited to how the product is identiﬁed
and sealed and if it follows established standards.
More thorough surveillance of microbiological contamination
of alcohol-free products used in adults predisposed to infection
should be mandatory. These ﬁndings highlight the importance of
hospital surveillance and the investigation of unusual clusters of
infection and colonization to promptly identify unexpected
sources of pathogens and to protect patients at risk. According
to Torbeck et al.,18 the drug manufacturing process should include
the microbiological screening of materials, equipment, and
environments, as well as the ﬁnal product, and the drugs should
be subjected to microbiological tests before use.
In conclusion, our ﬁndings strongly suggest that alcohol-free
mouthwash solution intrinsically contaminated with B. cepacia
was the source of these colonizations and infections involving
adults in the ICU. B. cepacia organisms are a clear and present
danger to patient health and safety. The challenge is undeniable:
there have been many outbreaks caused by B. cepacia reported in
the medical literature. Removing it from pharmaceutical
manufacturing areas and products will not be easy, but it must
be done.
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